RxDoctor Payments Data

Saraceli Salas

Medical · Brownsville, TXNPI 1356072052

Payments from drug & device makers

$1,298in general payments, 2019–2025

Across 55 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$319
  • AbbVie$316
  • Johnson & Johnson$269
  • Madrigal Pharmaceuticals$160
  • Phathom Pharmaceuticals, Inc.$96
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$47
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$1,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,298 in reported general payments places this provider in the 60th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$22,262
Medicare patients
210
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide37$24,403
Sucralfate50$3,199
Omeprazole128$1,455
Esomeprazole Magnesium33$1,415
Famotidine101$1,315
CholestyramineCholestyramine (With Sugar)15$991
Pantoprazole Sodium86$723
Lansoprazole11$421
Ondansetron OdtOndansetron14$374
Ondansetron Hcl21$283
Dicyclomine Hcl13$200
Hydrocortisone15$147
Metoclopramide Hcl19$99
Spironolactone13$78
Furosemide12$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$316$24,40337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,490 medical providers in Texas.

Other medical in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →